[PDF][PDF] Anifrolumab, an anti–interferon‐α receptor monoclonal antibody, in moderate‐to‐severe systemic lupus erythematosus
R Furie, M Khamashta, JT Merrill… - Arthritis & …, 2017 - Wiley Online Library
Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
R Furie, M Khamashta, JT Merrill… - Arthritis & …, 2017 - search.ebscohost.com
Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with …
antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with …
Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
R Furie, M Khamashta, JT Merrill… - Arthritis & …, 2017 - Wiley Online Library
Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
R Furie, M Khamashta, JT Merrill… - Arthritis & …, 2017 - escholarship.org
ObjectiveTo assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with …
antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with …
Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
R Furie, M Khamashta, JT Merrill, VP Werth… - Arthritis & …, 2017 - infona.pl
Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …
[PDF][PDF] Anifrolumab, an Anti–Interferon-a Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
R Furie, M Khamashta, JT Merrill, VP Werth, K Kalunian… - core.ac.uk
Objective. To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double-blind, placebocontrolled study of adults with …
antagonist, in a phase IIb, randomized, double-blind, placebocontrolled study of adults with …
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
R Furie, M Khamashta, JT Merrill… - Arthritis & …, 2017 - pubmed.ncbi.nlm.nih.gov
Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with …
antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with …
[PDF][PDF] Anifrolumab, an Anti–Interferon-a Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
R Furie, M Khamashta, JT Merrill, VP Werth, K Kalunian… - kclpure.kcl.ac.uk
Objective. To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double-blind, placebocontrolled study of adults with …
antagonist, in a phase IIb, randomized, double-blind, placebocontrolled study of adults with …
[PDF][PDF] Anifrolumab, an Anti–Interferon-a Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
R Furie, M Khamashta, JT Merrill, VP Werth, K Kalunian… - uab.edu
Objective. To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double-blind, placebocontrolled study of adults with …
antagonist, in a phase IIb, randomized, double-blind, placebocontrolled study of adults with …
Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
R Furie, M Khamashta, JT Merrill, VP Werth… - Arthritis & …, 2017 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Objective</jats: title>< jats: p> To assess the efficacy and safety
of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized …
of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized …